Retrophin (NASDAQ:RTRX) Reaches New 52-Week Low at $10.89

Retrophin Inc (NASDAQ:RTRX)’s share price reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $10.89 and last traded at $10.90, with a volume of 47216 shares trading hands. The stock had previously closed at $11.05.

A number of equities research analysts have recently issued reports on the stock. Leerink Swann set a $35.00 price target on shares of Retrophin and gave the company a “buy” rating in a research note on Thursday, August 22nd. ValuEngine raised shares of Retrophin from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Zacks Investment Research raised shares of Retrophin from a “sell” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Wednesday. Nomura reduced their price target on shares of Retrophin from $57.00 to $33.00 and set a “buy” rating on the stock in a research note on Friday, August 23rd. Finally, BMO Capital Markets reduced their price target on shares of Retrophin from $38.00 to $33.00 and set an “outperform” rating on the stock in a research note on Friday, August 23rd. One investment analyst has rated the stock with a sell rating and eleven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $27.63.

The firm’s 50 day moving average is $12.15 and its two-hundred day moving average is $17.96. The stock has a market capitalization of $475.46 million, a PE ratio of -4.40 and a beta of 0.80. The company has a debt-to-equity ratio of 0.72, a quick ratio of 4.99 and a current ratio of 5.05.

Retrophin (NASDAQ:RTRX) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.27). Retrophin had a negative return on equity of 47.21% and a negative net margin of 83.94%. The business had revenue of $44.71 million for the quarter, compared to analysts’ expectations of $43.01 million. During the same period in the previous year, the company earned ($0.25) earnings per share. Retrophin’s quarterly revenue was up 8.2% on a year-over-year basis. On average, analysts anticipate that Retrophin Inc will post -4.03 EPS for the current year.

In related news, insider Noah L. Rosenberg sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $19.95, for a total transaction of $49,875.00. Following the sale, the insider now directly owns 14,750 shares of the company’s stock, valued at approximately $294,262.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. 4.32% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in RTRX. Sphera Funds Management LTD. increased its stake in Retrophin by 33.8% during the 1st quarter. Sphera Funds Management LTD. now owns 435,678 shares of the biopharmaceutical company’s stock worth $9,859,000 after buying an additional 110,000 shares during the period. Handelsbanken Fonder AB increased its stake in Retrophin by 32.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 612,856 shares of the biopharmaceutical company’s stock worth $12,312,000 after buying an additional 150,000 shares during the period. Strs Ohio increased its stake in Retrophin by 7.4% during the 2nd quarter. Strs Ohio now owns 34,700 shares of the biopharmaceutical company’s stock worth $697,000 after buying an additional 2,400 shares during the period. Virginia Retirement Systems ET AL increased its stake in Retrophin by 12.7% during the 2nd quarter. Virginia Retirement Systems ET AL now owns 23,100 shares of the biopharmaceutical company’s stock worth $464,000 after buying an additional 2,600 shares during the period. Finally, Fisher Asset Management LLC increased its stake in Retrophin by 20.5% during the 2nd quarter. Fisher Asset Management LLC now owns 60,190 shares of the biopharmaceutical company’s stock worth $1,209,000 after buying an additional 10,260 shares during the period.

Retrophin Company Profile (NASDAQ:RTRX)

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Recommended Story: What is a Reverse Stock Split?

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.